Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009;12(3):261-4.
doi: 10.1007/s11102-008-0154-y.

Future treatment strategies of aggressive pituitary tumors

Steven W J Lamberts  1 , Leo J Hofland
Affiliations
Review

Future treatment strategies of aggressive pituitary tumors

Steven W J Lamberts et al. Pituitary. 2009.

Abstract

While surgery remains the first-line treatment of most aggressive pituitary adenomas, medical therapy is important as second-line or adjunctive therapy in a large proportion of patients. Dopamine agonists (DAs) are the best treatment for prolactinomas, but when DAs are not tolerated, new somatostatin receptor subtype 5 (SSTR(5)) inhibitors may offer an alternative in the future. Unfortunately, these are unlikely to be effective in DA-resistant prolactinomas. In acromegaly, the existing somatostatin analogs, octreotide and lanreotide, will remain the medical treatment of choice for the foreseeable future. There is an urgent need for medical therapies in Cushing's disease, and the SSTR(5) analogs could offer an effective treatment in a proportion of patients within the next few years. Finally, the medical management options for non-functioning pituitary adenomas are also very limited, and a new chimeric agent with activity towards dopamine receptors, SSTR(5) and SSTR(2) may help reduce adenoma recurrence in the future.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Effect of SSTR5-specific analog on prolactin secretion from DA-susceptible and DA-resistant human prolactinomas. From Jaquet et al. [1]
Fig. 2
Fig. 2
Pro-apoptotic effects of different somatostatin analogs in human somatotroph tumors. From Ferrante et al. [7]
Fig. 3
Fig. 3
[3H]-thymidine uptake inhibition from cell culture of 38 non-functioning pituitary adenomas by cabergoline, octreotide and dopastatin. From Florio et al. [20]
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1210/jc.84.9.3268', 'is_inner': False, 'url': 'https://doi.org/10.1210/jc.84.9.3268'}, {'type': 'PubMed', 'value': '10487698', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10487698/'}]}
    2. Jaquet P, Ouafik L, Saveanu A et al (1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84(9):3268–3276. doi:10.1210/jc.84.9.3268 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1210/jc.2003-031344', 'is_inner': False, 'url': 'https://doi.org/10.1210/jc.2003-031344'}, {'type': 'PubMed', 'value': '15070915', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15070915/'}]}
    2. Hofland LJ, van der Hoek J, van Koetsveld PM et al (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89(4):1577–1585. doi:10.1210/jc.2003-031344 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1210/jc.83.9.3308', 'is_inner': False, 'url': 'https://doi.org/10.1210/jc.83.9.3308'}, {'type': 'PubMed', 'value': '9745446', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9745446/'}]}
    2. Chaidarun SS, Swearingen B, Alexander JM (1998) Differential expression of estrogen receptor-beta (ER beta) in human pituitary tumors: functional interactions with ER alpha and a tumor-specific splice variant. J Clin Endocrinol Metab 83(9):3308–3315. doi:10.1210/jc.83.9.3308 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1023/A:1009903603495', 'is_inner': False, 'url': 'https://doi.org/10.1023/a:1009903603495'}, {'type': 'PubMed', 'value': '11081186', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11081186/'}]}
    2. Kaptain GJ, Simmons NE, Alden TD, Lopes MB, Vance ML, Laws ER (1999) Estrogen receptors in prolactinomas: a clinico-pathological study. Pituitary 1(2):91–98. doi:10.1023/A:1009903603495 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1210/er.2005-9998', 'is_inner': False, 'url': 'https://doi.org/10.1210/er.2005-9998'}, {'type': 'PubMed', 'value': '16705142', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16705142/'}]}
    2. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534. doi:10.1210/er.2005-9998 - PubMed

MeSH terms